Regulus Therapeutics Inc
RGLS8.160USD
+0.020+0.25%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
540.87MCap. mercado
PérdidaP/E TTM
Más Datos de Regulus Therapeutics Inc Compañía
Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing drugs targeting microRNAs to treat diseases with significant unmet medical need. The Company is focused on orphan kidney diseases where microRNA genetic drivers are implicated and there are clear unmet medical needs. Its product candidate, RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), is in Phase 1b clinical development. In addition to this program, the Company continues to advance and expand its internal discovery pipeline to identify potential product candidates. microRNAs are naturally occurring ribonucleic acid (RNA) molecules that play a critical role in regulating key biological pathways. ADPKD is among the common human monogenic disorders and a cause of end-stage renal disease.
Información de la empresa
Símbolo de cotizaciónRGLS
Nombre de la empresaRegulus Therapeutics Inc
Fecha de salida a bolsaOct 04, 2012
Director ejecutivoMr. Joseph P. (Jay) Hagan
Número de empleados34
Tipo de seguridadOrdinary Share
Fin del año fiscalOct 04
Dirección4224 Campus Point Court
CiudadSAN DIEGO
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal92121
Teléfono18582026300
Sitio Webhttps://www.regulusrx.com/
Símbolo de cotizaciónRGLS
Fecha de salida a bolsaOct 04, 2012
Director ejecutivoMr. Joseph P. (Jay) Hagan
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Crispina Calsada, CPA
Ms. Crispina Calsada, CPA
Chief Financial Officer
Chief Financial Officer
56.73K
+24.74%
Mr. Christopher Ray Aker, J.D.
Mr. Christopher Ray Aker, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
50.55K
+402.65%
Mr. John Mckenna
Mr. John Mckenna
President, Director
President, Director
--
--
Mr. Eduard Marti
Mr. Eduard Marti
Director
Director
--
--
Ms. Rekha Garg
Ms. Rekha Garg
Chief Medical Officer
Chief Medical Officer
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Crispina Calsada, CPA
Ms. Crispina Calsada, CPA
Chief Financial Officer
Chief Financial Officer
56.73K
+24.74%
Mr. Christopher Ray Aker, J.D.
Mr. Christopher Ray Aker, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
50.55K
+402.65%
Mr. John Mckenna
Mr. John Mckenna
President, Director
President, Director
--
--
Mr. Eduard Marti
Mr. Eduard Marti
Director
Director
--
--
Ms. Rekha Garg
Ms. Rekha Garg
Chief Medical Officer
Chief Medical Officer
--
--
Desglose de ingresos
FY2021
FY2020
FY2019
Sin datos
Por regiónUSD
Nombre
Ganancia
Proporción
United States
0.00
0.00%
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: jue., 3 de jul
Actualizado: jue., 3 de jul
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Federated Hermes Global Investment Management Corp.
22.85%
New Enterprise Associates (NEA)
9.34%
Octagon Capital Advisors LP
6.70%
The Vanguard Group, Inc.
5.71%
BlackRock Institutional Trust Company, N.A.
5.53%
Other
49.87%
Accionistas
Accionistas
Proporción
Federated Hermes Global Investment Management Corp.
22.85%
New Enterprise Associates (NEA)
9.34%
Octagon Capital Advisors LP
6.70%
The Vanguard Group, Inc.
5.71%
BlackRock Institutional Trust Company, N.A.
5.53%
Other
49.87%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor/Hedge Fund
31.40%
Hedge Fund
24.30%
Venture Capital
13.25%
Investment Advisor
12.88%
Individual Investor
0.80%
Research Firm
0.77%
Bank and Trust
0.11%
Pension Fund
0.08%
Other
16.42%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
1
--
0.00%
-90.00
2025Q1
151
57.15M
82.75%
-7.04M
2024Q4
137
55.74M
85.10%
-6.54M
2024Q3
128
58.95M
90.05%
-6.89M
2024Q2
113
63.43M
96.89%
+3.08M
2024Q1
85
60.55M
95.51%
+47.86M
2023Q4
70
12.67M
62.78%
-270.56K
2023Q3
77
12.73M
68.68%
-335.94K
2023Q2
80
12.00M
64.97%
-983.27K
2023Q1
89
9.82M
61.73%
-1.56M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Federated Hermes Global Investment Management Corp.
15.82M
22.85%
+2.97M
+23.09%
Mar 31, 2025
New Enterprise Associates (NEA)
6.47M
9.34%
--
--
Mar 31, 2025
Octagon Capital Advisors LP
4.64M
6.7%
-211.73K
-4.37%
Mar 31, 2025
The Vanguard Group, Inc.
3.95M
5.71%
-14.97K
-0.38%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.83M
5.53%
-64.74K
-1.66%
Mar 31, 2025
Point72 Asset Management, L.P.
3.68M
5.32%
+1.71M
+87.10%
Apr 01, 2025
Deep Track Capital LP
3.26M
4.71%
--
--
Mar 31, 2025
Vivo Capital, LLC
2.70M
3.89%
-2.30M
-46.07%
Mar 31, 2025
Baker Bros. Advisors LP
2.69M
3.89%
+2.69M
--
Mar 31, 2025
Geode Capital Management, L.L.C.
1.30M
1.88%
+21.49K
+1.68%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: dom., 6 de jul
Actualizado: dom., 6 de jul
Nombre
Proporción
iShares Micro-Cap ETF
0.11%
iShares Russell 2000 Value ETF
0.03%
Global X Russell 2000 ETF
0.02%
iShares Russell 2000 ETF
0.02%
ProShares UltraPro Russell2000
0.02%
ProShares Hedge Replication ETF
0.02%
Proshares Ultra Russell 2000
0.02%
iShares Russell 2000 Growth ETF
0.01%
iShares Core S&P Total U.S. Stock Market ETF
0%
Avantis US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
Proporción0.11%
iShares Russell 2000 Value ETF
Proporción0.03%
Global X Russell 2000 ETF
Proporción0.02%
iShares Russell 2000 ETF
Proporción0.02%
ProShares UltraPro Russell2000
Proporción0.02%
ProShares Hedge Replication ETF
Proporción0.02%
Proshares Ultra Russell 2000
Proporción0.02%
iShares Russell 2000 Growth ETF
Proporción0.01%
iShares Core S&P Total U.S. Stock Market ETF
Proporción0%
Avantis US Small Cap Equity ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Jun 28, 2022
Merger
10<1
Jun 28, 2022
Merger
10<1
Jun 28, 2022
Merger
10<1
Jun 28, 2022
Merger
10<1
Fecha
Tipo
Relación
Jun 28, 2022
Merger
10<1
Jun 28, 2022
Merger
10<1
Jun 28, 2022
Merger
10<1
Jun 28, 2022
Merger
10<1
